Jane Street
ODT

Jane Street’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Jane Street’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-56,800
Closed -$194K – 10757
2021
Q1 		$194K Buy
+56,800
New +$1.07M ﹤0.01% 8296

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Jane Street's ODT Position: Q1 2022 in Review

Jane Street sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 13,801 shares — an estimated $19K sold.

Jane Street first reported a position in ODT in Q2 2020 and held it in 4 quarters. The position peaked at $257K in Q2 2020. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • Jane Street reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Jane Street sold 13,801 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $19K.
  • Jane Street first reported a position in Odonate Therapeutics, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
  • Jane Street's Odonate Therapeutics, Inc. Common Stock position peaked at $257K in Q2 2020.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Jane Street's 13F filing for Q1 2022, filed 17 May 2022.